These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 263873)
1. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. Weibel RE; Buynak EB; McLean AA; Hilleman MR Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Weibel RE; Buynak EB; McLean AA; Hilleman MR Pediatrics; 1975 Sep; 56(3):380-7. PubMed ID: 1161394 [TBL] [Abstract][Full Text] [Related]
3. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine. Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780 [TBL] [Abstract][Full Text] [Related]
4. Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines. Weibel RE; Buynak EB; Stokes J; Hilleman MR Pediatrics; 1973 Mar; 51(3):467-75. PubMed ID: 4707864 [No Abstract] [Full Text] [Related]
5. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children. Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276 [TBL] [Abstract][Full Text] [Related]
6. [Experience with preventive measles, mumps and rubella vaccination in unified Germany]. Gerike E; Tischer A Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543 [TBL] [Abstract][Full Text] [Related]
7. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K; Nicoara C; Germann D; Matter L Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837 [TBL] [Abstract][Full Text] [Related]
8. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella]. Trier H; Rønne T Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566 [TBL] [Abstract][Full Text] [Related]
9. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine. André FE; Peetermans J Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770 [TBL] [Abstract][Full Text] [Related]
10. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126 [TBL] [Abstract][Full Text] [Related]
11. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Lerman SJ; Bollinger M; Brunken JM Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582 [TBL] [Abstract][Full Text] [Related]
12. Comparative study and evaluation of further attenuated, live measles vaccines alone and in combination with mumps and rubella vaccines. Wegmann A; Glück R; Just M; Mischler R; Paroz P; Germanier R Dev Biol Stand; 1986; 65():69-74. PubMed ID: 3556778 [TBL] [Abstract][Full Text] [Related]
13. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines. Weibel RE; Buynak EB; McLean AA; Roehm RR; Hilleman MR Proc Soc Exp Biol Med; 1980 Nov; 165(2):260-3. PubMed ID: 7443713 [No Abstract] [Full Text] [Related]
14. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps. Smorodintsev AA; Nasibov MN; Jakovleva NV Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140 [TBL] [Abstract][Full Text] [Related]
15. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673 [TBL] [Abstract][Full Text] [Related]
16. Studies on live rubella vaccine. V. Quantitative aspects of interference between rubella, measles and mumps viruses in their trivalent vaccine. Minekawa Y; Ueda S; Yamanishi K; Ogino T; Takahashi M Biken J; 1974 Dec; 17(4):161-7. PubMed ID: 4464833 [TBL] [Abstract][Full Text] [Related]
17. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM; Saunders EF; Petric M; Gold R Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367 [TBL] [Abstract][Full Text] [Related]
18. A field with a liver measles-mumps-rubella vaccine. Walters VW; Miller SA; Jackson JE; Kenny MT Clin Pediatr (Phila); 1975 Oct; 14(10):928-33. PubMed ID: 1100294 [TBL] [Abstract][Full Text] [Related]
19. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella]. Just M; Berger R; Glück R; Wegmann A Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704 [TBL] [Abstract][Full Text] [Related]
20. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine]. Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]